The News

DIATOS S.A. opens its US subsidiary in California – DIATOS USA, INC.

17/05/2005

PARIS, FRANCE & PALO ALTO, CA – April 12, 2005 – Diatos S.A., a privately held biopharmaceutical company, announced today the expansion of its operations with the opening of a new subsidiary, Diatos USA, Inc., with business offices located on the West Coast of the United States. Gordon M. Saul, Executive in-Residence at InterWest Partners, has been appointed Managing Director and Chief Business Officer of Diatos USA, Inc.

Diatos has been operating in the US for some time, with a business representative in the San Francisco Bay Area.  However, because the company is expanding its pipeline and moving products into clinical trials, it is taking on a more global presence. The US subsidiary will support the development and business efforts of Diatos in the United States.

“Our activities in the US are likely to become more significant, in view of our continuing international development and the expansion of our product pipeline,” commented John Tchelingerian, Ph.D., Diatos S.A. President and Chief Executive Officer, and now also Chairman and President of Diatos USA, Inc.  “I am very pleased that Gordon Saul, a highly qualified business executive, will be leading our expansion efforts in the US.”

“I am excited to be working with Diatos at this stage of the company’s growth,” said Mr. Saul.  “The company has the proprietary technology, financial strength and development expertise to support its global commercialization program for cancer therapeutics.  Diatos is internationally recognized as a leader in its field.”

About Diatos
Diatos is using its proprietary Diatos Peptide Vector (DPV/Vectocell®) intra-cellular/intra-nuclear delivery technology and its proprietary Tumor-Selective Prodrug (TSP) cancer-targeting technology to develop new therapies for cancer and other serious diseases. The company’s lead therapeutic candidates, DTS-201 – a doxorubicin prodrug based on the TSP technology concept – and DTS-301 – a novel paclitaxel formulation – are respectively entering Phase I and Phase II clinical trials in 2005.

Diatos has raised 33 million Euros to date from Sofinnova Partners (France), GIMV (Belgium), InterWest Partners (USA), Credit Agricole Private Equity (France), AGF Private Equity (France), NIF Ventures (Japan), Société Générale Asset Management (France), Sopartec (Belgium), Innoven Partenaires (France) and BFF (Belgium). Diatos is headquartered in Paris and has operations in Belgium and the USA, with a total of 44 employees.

Contacts :
Diatos S.A. 
John Tchelingerian, Ph.D., President & CEO 
c/o Astrid Heinesch, 
Assistant to General Management 
+33-1-53-80-93-62 
jtchelingerian@diatos.com

Diatos U.S.A., Inc.
Gordon M. Saul, Managing Director & CBO
+1-650-269-6141
gsaul@diatos.com